A Phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2

Press/Media: Press / Media

PeriodApr 30 2015

Media coverage

1

Media coverage

  • TitleA Phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2
    Media name/outletNational AIDS Treatment Advocacy Project
    CountryUnited States
    Date4/30/15
    PersonsEric J Lawitz